[{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLOB","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ALLOB","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"ALLOB","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Catalent Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"Sodium ion channel","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Milvexian","moa":"Factor XIa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Janssen Pharmaceuticals"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Hypoxic Cultured Mesenchymal Stem Cells","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ PRC Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ PRC Clinical"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$5.0 million","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","upfrontCash":"$9.7 million","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Pregene"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Merger","leadProduct":"Allogeneic Plasma-based Biomaterial","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"}]
Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
